Emergent high fatality lung disease in systemic juvenile arthritis

scientific article published on 27 September 2019

Emergent high fatality lung disease in systemic juvenile arthritis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/ANNRHEUMDIS-2019-216040
P932PMC publication ID7065839
P698PubMed publication ID31562126

P50authorRandy Quentin CronQ41541880
Fabrizio De BenedettiQ56394747
Purvesh KhatriQ57163305
Ying LuQ59747997
Gill BejeranoQ88164421
Elizabeth D MellinsQ89700108
Edward M BehrensQ90341329
Dieneke Schonenberg-MeinemaQ92921580
P2093author name stringJohannes Roth
Diana Milojevic
Karen Onel
Lisa R Young
Matthew L Stoll
Rayfel Schneider
Richard K Vehe
Sampath Prahalad
Mark M Davis
Christi J Inman
Lu Tian
Sara O Vargas
Judith A Smith
Jianpeng Xu
Tushar Desai
Seza Ozen
Marisa Klein-Gitelman
Melissa Hazen
Alexei A Grom
Gail H Deutsch
Susan Shenoi
Robin Deterding
Maria Perez
R Paul Guillerman
Kevin Baszis
T Brent Graham
Christopher Towe
Jenny Lin
Deborah R Liptzin
Hafize Emine Sönmez
Alicia Casey
Maria Ibarra
Raymond Balise
Ann N Leung
Aliva De
Vivian E Saper
Ian Ferguson
Johannes Birgmeier
Clara Lin
Lauren A Henderson
Guangbo Chen
Martha P Fishman
Childhood Arthritis and Rheumatology Research Alliance Registry Investigators
Grant Schulert
Layla Bouzoubaa
Daniel J Kingsbury
Sivia Lapidus
Rita Jerath
Khalid Abulaban
Kathleen Haines
Adam Reinhardt
Karthik Jagadeesh
Suhas Radhakrishna
Scott Canna
Jacqueline Yang
James Birmingham
Assunta Ho
Joy Mombourquette
Kathryn Phillippi
Khanh Lai
Khulood Khawaja
Michal Cidon
Mona Riskalla
Natalie Rosenwasser
Steven I Goodman
P2860cites workConsensus treatment plans for new-onset systemic juvenile idiopathic arthritisQ24610145
Genetic disorders of surfactant dysfunctionQ28235256
Endogenous lipoid pneumonia preceding diagnosis of pulmonary alveolar proteinosisQ28245541
Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).Q31140276
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritisQ33404895
The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 monthsQ33568429
Age-dependent levels of select immunological mediators in sera of healthy childrenQ33992976
Pulmonary alveolar proteinosis: progress in the first 44 yearsQ34139014
Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosisQ34239936
Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humansQ34475541
Diffuse lung disease in young children: application of a novel classification schemeQ34691602
The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells.Q34749235
Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective studyQ35035794
Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosisQ35064189
Pathologic characteristics of drug-induced lung diseaseQ35736979
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritisQ35766646
Abdominal and pelvic CT in the HIV-positive populationQ35936526
Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion IslandQ36060847
Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33.Q36131723
Interleukin 1: an important mediator of host resistance against Pneumocystis cariniiQ36231708
Single ABCA3 mutations increase risk for neonatal respiratory distress syndromeQ36425766
Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.Q36979961
Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.Q36979986
Parenchymal lung involvement in adult-onset Still disease: A STROBE-compliant case series and literature reviewQ37605617
Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndromeQ37770687
Infections and immunodeficiency in Down syndromeQ37847219
Thoracic findings of systemic diseases at high-resolution CT in childrenQ37854279
Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful?Q37871716
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung diseaseQ38006923
Diffuse and interstitial lung disease and childhood rheumatologic disordersQ38028313
Pulmonary complications of biological therapies in children and adults with rheumatic diseases.Q38086674
Patient characteristics and severity of human rhinovirus infections in childrenQ38124148
Translational research in pediatrics III: bronchoalveolar lavageQ38225086
Inflammasomes and its importance in viral infections.Q38971599
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune featuresQ38986306
Pharmacotherapeutic Considerations for Individuals with Down SyndromeQ39032991
Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA).Q39413814
Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.Q39663220
Defective Lung Macrophages in Pulmonary Alveolar ProteinosisQ40012602
The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.Q40101219
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.Q40198507
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR studyQ40241303
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritisQ40263864
Pulmonary manifestations of juvenile rheumatoid arthritis. A report of eight cases and reviewQ40317853
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter seriesQ40335671
The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis familiesQ40546279
Morbidity and medication in a large population of individuals with Down syndrome compared to the general populationQ40634094
Inhibiting NF-κB in the developing lung disrupts angiogenesis and alveolarizationQ41824496
The great mimickers: Castleman disease.Q42210448
A 21-year-old man with systemic-onset juvenile rheumatoid arthritis, cough and progressive dyspnea.Q42231947
GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosisQ42508031
Genetic testing in children with surfactant dysfunctionQ43440530
Coexisting endogenous lipoid pneumonia, cholesterol granulomas, and pulmonary alveolar proteinosis in a pediatric population: a clinical, radiographic, and pathologic correlationQ43740939
Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation.Q44645053
Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutationsQ44680196
Familial interstitial disease with I73T mutation: A mid- and long-term studyQ44728463
Refined characterization and reference values of the pediatric T- and B-cell compartmentsQ45191073
Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failureQ47725434
Mortality rates are increased in patients with systemic juvenile idiopathic arthritis.Q48258658
IL-1α promotes pathogenic immature myeloid cells and IL-1β favors protective mature myeloid cells during acute lung infection.Q49650563
Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoidsQ50180205
Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep LearningQ50421386
New interplay between interstitial and alveolar macrophages explains pulmonary alveolar proteinosis (PAP) induced by indium tin oxide particles.Q52683960
IL-1α induces CD11blow alveolar macrophage proliferation and maturation during granuloma formationQ56834530
Drug-Induced Interstitial Lung Disease: A Systematic ReviewQ57463653
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registriesQ60930184
Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center ExperienceQ61911597
Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritisQ67771315
Bronchoalveolar lavage studies in children without parenchymal lung disease: cellular constituents and protein levelsQ70921804
Diffuse progressive pulmonary interstitial and intra-alveolar cholesterol granulomas in childhoodQ71841452
Clinical, radiological and pathological features of ABCA3 mutations in childrenQ79909696
Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drugQ80133101
Pulmonary alveolar proteinosis in pediatric leukemiaQ80214199
Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcomeQ85901996
Comments on: DRESS syndromeQ86087419
Hypersensitivity Reactions to Antiepileptic Drugs in Children: Epidemiologic, Pathogenetic, Clinical, and Diagnostic AspectsQ90925974
Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come?Q91083949
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up StudyQ92219527
Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk FactorsQ92399558
Severe hypersensitivity reactions to biological drugs in children with rheumatic diseasesQ92661176
P433issue12
P921main subjectlung diseaseQ3392853
P304page(s)1722-1731
P577publication date2019-09-27
P1433published inAnnals of the Rheumatic DiseasesQ4767876
P1476titleEmergent high fatality lung disease in systemic juvenile arthritis
P478volume78

Reverse relations

cites work (P2860)
Q90709366Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?
Q89564969Keeping up with the progress in the diagnosis and management of pediatric rheumatic diseases
Q97568272Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
Q96647317Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
Q90661480Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis

Search more.